Medswap Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
- Revenue Growth 75.72%
- Profit Growth 74.54%
- Ebitda 63.37%
- Net Worth 20.13%
- Total Assets 65.41%
About Medswap Pharmaceuticals
Medswap Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 May 2017 (Seven years and nine months 12 days old ). Its registered office is in Kolhapur, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Swapnil Jadhav and Geeta Jadhav serve as directors at the Company.
Company Details
-
Location
Kolhapur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24100PN2017PTC170327
-
Company No.
170327
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 May 2017
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Medswap Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swapnil Jadhav
|
Director | 05-May-2017 | Current |
|
Geeta Jadhav
|
Director | 05-May-2017 | Current |
Financial Performance of Medswap Pharmaceuticals.
Medswap Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 75.72% increase. The company also saw a substantial improvement in profitability, with a 74.54% increase in profit. The company's net worth Soared by an impressive increase of 20.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medswap Pharmaceuticals?
In 2023, Medswap Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2022 | Others | ₹0.50 M | Open |
How Many Employees Work at Medswap Pharmaceuticals?
Unlock and access historical data on people associated with Medswap Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medswap Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medswap Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.